~$6m average in economic activity per donor centre – driven by donor payments, employee wages and local community spending This Impact Report highlights our work in financial year 2025 (FY2025) to create lifesaving medicines, safeguard public health, advance science and contribute positively to the communities where we live and work. Note The 2025 financial year is from 1 July 2024 – 30 June 2025. All financial figures are reported in USD unless otherwise indicated. Disclaimer This Impact Report is produced by CSL Limited (ACN 051 588 348) for general information purposes only. While effort has been made to ensure the accuracy and completeness of the information at the time of publication, CSL makes no representations or warranties of any kind, express or implied, about the content’s accuracy, reliability, or suitability. All content is the property of CSL or its licensors and is protected by applicable intellectual property laws. Reproduction is permitted only for personal, non-commercial use and must retain all proprietary notices. Some statements about products, registered product indications or procedures may differ in certain countries. Therefore, always consult the country‑specific product information, package leaflets or instructions for use. For more information, please contact a local CSL representative. Brand names designated by a ® or a ™ throughout this publication are trademarks either owned by and/or licensed to CSL or its affiliates. Not all brands mentioned are used or registered as trademarks in all countries served by CSL. Our Impact $350k to humanitarian aid 2 Limited Our Impact 2025 From our CEO Lifesaving Medicines Healthier Communities Science and Medicine Legacy About CSL 8.8m patients treated with plasma-derived and recombinant therapies 56 new product registrations and indications in FY2025 providing more treatment options to patients with serious diseases >101m seasonal flu vaccines distributed globally 59 clinical trials underway (across clinical, registration and post launch) to find solutions to unmet needs $24m contributed to support patient communities $1m in contributions to local communities $10.3m contributed to science and innovation to advance knowledge, research and careers in biomedicine
RkJQdWJsaXNoZXIy MjE2NDg3